Public trial registry of the CCC-Munich

Trial BRF117277 GlaxoSmithKline

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
BRF117277 GlaxoSmithKline
World
Full title
:

A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain

World
Description
:

This is a multi-cohort, open label, Phase II study with dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy in subjects with BRAF Mutation-Positive Melanoma that has metastasized to the Brain. This study will evaluate the safety and efficacy of 4 cohorts. Local therapy is referred to as therapy to the brain throughout
this protocol even if not identified as such.
 Cohort A: Seventy-five subjects with centrally confirmed BRAF V600E
cutaneous melanoma with metastases to the brain confirmed by MRI,
asymptomatic, without prior local (brain) therapy and ECOG score of 0-1.
 Cohort B: Fifteen subjects with locally confirmed BRAF V600E cutaneous
melanoma with metastases to the brain confirmed by MRI, asymptomatic, with
prior local (brain) therapy and ECOG score of 0-1.
 Cohort C: Up to fifteen subjects with locally confirmed BRAF V600 D/K/R
cutaneous melanoma with metastases to the brain confirmed by MRI,
asymptomatic, with or without prior local (brain) therapy and ECOG score of 0-
1.
 Cohort D: Fifteen subjects with locally confirmed BRAF V600 D/E/K/R
cutaneous melanoma with metastases to the brain confirmed by MRI,symptomatic, with or without prior local (brain) therapy and ECOG score of 0-2.
Subjects will receive dabrafenib capsules 150 mg twice daily and trametinib tablets 2 mg
once daily until evidence of disease progression, death, or unacceptable toxicity.
Subjects will be required to meet all eligibility criteria and return to clinic on a monthly basis for clinical and laboratory assessments. Intracranial and extracranial disease will be assessed at baseline, Week 4, Week 8, and every 8 weeks thereafter. After Week 40, disease assessments may be performed every 12 weeks. Response to treatment will be
evaluated using modified Response Evaluation Criteria in Solid Tumours (RECIST)version 1.1 [Eisenhauer, 2009].
Treatment will continue in all cohorts until disease progression, death, unacceptable
toxicity, or withdrawal of consent. After treatment discontinuation, subjects will be followed for skin assessments, survival and disease progression as applicable.

World
EudraCT number
:
World
Responsible organization
:
KUM - Klinik und Poliklinik für Dermatologie und Allergologie, München Lmu
Indications
Classification Code Description
ICD-10-GM C43.9 Bösartiges Melanom der Haut, nicht näher bezeichnet
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Open
World
Phase
:
II
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Positive
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Participants
Function Prename Surname Organization
World Responsible contact Carola Berking KUM - Klinik und Poliklinik für Dermatologie und Allergologie Magnifier
World Sponsor GSK Magnifier
World Principal Investigator Carola Berking KUM - Klinik und Poliklinik für Dermatologie und Allergologie Magnifier